Ondrej Slaby

Summary

Publications

  1. Slaby O, Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, et al. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer. 2012;51:707-16 pubmed publisher
    ..If further validated, we suggest that identified miRNAs might be used for identification of RCC patients at high risk of early relapse after nephrectomy in clinical practice. ..
  2. request reprint
    Vychytilova Faltejskova P, Pesta M, Radova L, Liska V, Daum O, Kala Z, et al. Genome-wide microRNA Expression Profiling in Primary Tumors and Matched Liver Metastasis of Patients with Colorectal Cancer. Cancer Genomics Proteomics. 2016;13:311-6 pubmed
    ..These results indicate that miRNAs could serve as new therapeutic targets in patients with metastatic CRC. ..
  3. Slaby O, Laga R, Sedlacek O. Therapeutic targeting of non-coding RNAs in cancer. Biochem J. 2017;474:4219-4251 pubmed publisher
    ..Finally, we provide the up-to-date summary of clinical trials involving miRNAs and future directions in the development of ncRNA therapeutics. ..
  4. request reprint
    Iliev R, Fedorko M, Machackova T, Mlcochova H, Svoboda M, Pacik D, et al. Expression Levels of PIWI-interacting RNA, piR-823, Are Deregulated in Tumor Tissue, Blood Serum and Urine of Patients with Renal Cell Carcinoma. Anticancer Res. 2016;36:6419-6423 pubmed
    ..In blood serum, piR-823 is up-regulated, but with unsatisfactory analytical performance. Preliminary data indicate the promising diagnostic utility of urinary piR-823 in patients with RCC. ..
  5. Vychytilova Faltejskova P, Slaby O. MicroRNA-215: From biology to theranostic applications. Mol Aspects Med. 2019;: pubmed publisher
  6. Ahmad P, Sana J, Slavik M, Gurín D, Radova L, Gablo N, et al. MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy. Cancer Genomics Proteomics. 2019;16:139-146 pubmed publisher
    ..25; 95% CI=0.05-0.78; p<0.016). miR-15b-5p represents a potentially helpful biomarker for individualized treatment decisions concerning the management of HNSCC patients. ..
  7. Juracek J, Staník M, Veselá P, Radova L, Dolezel J, Svoboda M, et al. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram. Urol Oncol. 2019;37:184.e1-184.e7 pubmed publisher
  8. Vecera M, Sana J, Lipina R, Smrcka M, Slaby O. Long Non-Coding RNAs in Gliomas: From Molecular Pathology to Diagnostic Biomarkers and Therapeutic Targets. Int J Mol Sci. 2018;19: pubmed publisher
    ..A conclusion follows that these RNAs show great potential to serve as powerful diagnostic, prognostic, and predictive biomarkers as well as therapeutic targets. ..
  9. Obermannová R, Redova Lojova M, Vychytilova Faltejskova P, Grell P, Cho W, Sachlova M, et al. Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population. Anticancer Res. 2018;38:3719-3724 pubmed publisher
    ..Our results indicate that selected tissue microRNAs have the potential to serve as relevant diagnostic and prognostic biomarkers of GC in a central European population. ..

More Information

Publications25

  1. request reprint
    Kovacova J, Juracek J, Poprach A, Buchler T, Kopecký J, Fiala O, et al. Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response. Anticancer Res. 2018;38:2961-2965 pubmed
    ..8071). Following further independent validation, detection of these miRNAs may prevent unnecessary and costly approaches to therapy in non-responding patients with mRCC. ..
  2. Hezova R, Kovarikova A, Srovnal J, Zemanova M, Harustiak T, Ehrmann J, et al. MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus. Tumour Biol. 2016;37:8007-18 pubmed publisher
    ..Our results suggest that miR-205 could serve as biomarker in esophageal cancer and acts as a tumor suppressor in esophageal adenocarcinoma and oncogene in esophageal squamous cell carcinoma. ..
  3. Slaby O. Non-coding RNAs as Biomarkers for Colorectal Cancer Screening and Early Detection. Adv Exp Med Biol. 2016;937:153-70 pubmed publisher
  4. Sana J, Busek P, Fadrus P, Besse A, Radova L, Vecera M, et al. Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival. Sci Rep. 2018;8:2836 pubmed publisher
    ..We propose that these miRNAs participate on GSC features and could represent helpful prognostic markers and potential therapeutic targets in GBM. ..
  5. Besse A, Sana J, Lakomy R, Kren L, Fadrus P, Smrcka M, et al. MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response. Tumour Biol. 2016;37:7719-27 pubmed publisher
    ..To our knowledge, this is the first study to describe the role of miR-338-5p in GBM and its potential to improve the sensitivity of GBM to radiation. ..
  6. Vychytilova Faltejskova P, Slaby O. Circulating Blood-Borne microRNAs as Biomarkers in Solid Tumors. Exp Suppl. 2015;106:75-122 pubmed publisher
    ..Here, we summarize the tumor-specific profiles of blood-borne microRNAs and discuss their potential utility for personalized medicine of solid tumors. ..
  7. request reprint
    Iliev R, Kleinova R, Juracek J, Dolezel J, Ozanova Z, Fedorko M, et al. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer. Tumour Biol. 2016;37:13385-13390 pubmed
    ..Together with in vitro observations, these data suggest an oncogenic role of TUG1 and its potential usage as biomarker or therapeutic target in MIBC. ..
  8. Lupini L, Bassi C, Mlcochova J, Musa G, Russo M, Vychytilova Faltejskova P, et al. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer. 2015;15:808 pubmed publisher
  9. Sana J, Radova L, Lakomy R, Kren L, Fadrus P, Smrcka M, et al. Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients. Carcinogenesis. 2014;35:2756-62 pubmed publisher
    ..We suggest that the Risk Score presents promising prognostic algorithm with potential for individualized treatment decisions in clinical management of GBM patients. ..
  10. request reprint
    Machackova T, Mlcochova H, Staník M, Dolezel J, Fedorko M, Pacik D, et al. MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition. Tumour Biol. 2016;37:14653-14658 pubmed
    ..We further suggest that miR-429 has a capacity to inhibit loss of E-cadherin in RCC cells undergoing EMT and consequently attenuate their motility. ..
  11. request reprint
    Ondracek J, Fadrus P, Sana J, Besse A, Loja T, Vecera M, et al. Global MicroRNA Expression Profiling Identifies Unique MicroRNA Pattern of Radioresistant Glioblastoma Cells. Anticancer Res. 2017;37:1099-1104 pubmed
    ..We believe that after deeper functional investigation of identified miRNAs in relation to radioresistance, these miRNAs present potential predictive biomarkers or therapeutic targets in GBM. ..
  12. Vychytilova Faltejskova P, Merhautova J, Machackova T, Gutierrez Garcia I, Garcia Solano J, Radova L, et al. MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9. Oncogenesis. 2017;6:399 pubmed publisher
  13. Hezova R, Kovarikova A, Srovnal J, Zemanova M, Harustiak T, Ehrmann J, et al. Diagnostic and prognostic potential of miR-21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus. Diagn Pathol. 2015;10:42 pubmed publisher
    ..The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/4646922201567057. ..
  14. Vychytilova Faltejskova P, Kiss I, Klusova S, Hlavsa J, Procházka V, Kala Z, et al. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Diagn Pathol. 2015;10:38 pubmed publisher
    ..The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1373952531543898. ..
  15. Slaby O, Srovnal J, Radova L, Gregar J, Juracek J, Luzna P, et al. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma. Carcinogenesis. 2015;36:521-7 pubmed publisher
  16. Slaby O, Sachlova M, Brezkova V, Hezova R, Kovarikova A, Bischofová S, et al. Identification of microRNAs regulated by isothiocyanates and association of polymorphisms inside their target sites with risk of sporadic colorectal cancer. Nutr Cancer. 2013;65:247-54 pubmed publisher
    ..072). This study showed that miRNAs could be involved in chemoprotective effects of natural agents; their function alteration through SNPs in their binding sites and flanking regions presents a new class of CRC risk factors. ..